Within risk thresholds ranging from 0 to 0.75, the curves for RPL22L1 and LY96 consistently surpassed both the "all" and "none" curves, suggesting that decision-making based on these marker genes may provide significant benefits for patients with PsA and RA. Here, LY96 is linked to rheumatoid arthritis.